Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;88(1):15-27.
doi: 10.1159/000512007. Epub 2020 Oct 13.

The Impact of COVID-19 Disease on Platelets and Coagulation

Affiliations
Review

The Impact of COVID-19 Disease on Platelets and Coagulation

Geoffrey D Wool et al. Pathobiology. 2021.

Abstract

Coronavirus disease 2019 (COVID-19) causes a spectrum of disease; some patients develop a severe proinflammatory state which can be associated with a unique coagulopathy and procoagulant endothelial phenotype. Initially, COVID-19 infection produces a prominent elevation of fibrinogen and D-dimer/fibrin(ogen) degradation products. This is associated with systemic hypercoagulability and frequent venous thromboembolic events. The degree of D-dimer elevation positively correlates with mortality in COVID-19 patients. COVID-19 also leads to arterial thrombotic events (including strokes and ischemic limbs) as well as microvascular thrombotic disorders (as frequently documented at autopsy in the pulmonary vascular beds). COVID-19 patients often have mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Here, we review the current state of knowledge of COVID-19 and hemostasis.

Keywords: COVID-19; Coagulopathy; D-dimer; Thrombocytopenia; Thrombosis.

PubMed Disclaimer

Conflict of interest statement

G.D.W. is on an advisory committee at Diagnostica Stago and receives honoraria. J.L.M. declares no conflicts of interest.

Figures

Fig. 1
Fig. 1
Relationship between platelet count and mean platelet volume (MPV) in a sample of ICU patients affected by COVID-19 (COVID+; n = 10, with 266 measurements) or not (COVID–; n = 10, with 91 measurements). These populations were significantly different from each other (Student's t test, p < 5 ×10−7).
Fig. 2
Fig. 2
Relationship between platelet count and immature platelet fraction (IPF) in a sample of thrombocytopenic ICU patients affected by COVID-19 (COVID+; n = 4, with 23 measurements) or not (COVID–; n = 4, with 23 measurements). a Absolute IPF counts. These populations were significantly different from each other (Student's t test, p < 0.005). b Relative IPF counts. Of note, the relative IPF counts for COVID+ patients did not form a strong enough relationship with platelet count to display a relevant trendline. These populations were significantly different from each other (Student's t test, p < 0.05).

References

    1. Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020 May;31((4)):490–6. - PMC - PubMed
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18((4)):844–7. - PMC - PubMed
    1. Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145–7. - PMC - PubMed
    1. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) Blood Transfus. 2020 May;18((3)):167–9. - PMC - PubMed
    1. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020 Apr;5((4)):562–9. - PMC - PubMed

MeSH terms

Substances